[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-pacing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-pacing":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,81,119,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100623159","biostreamcsp-study-100623159",false,"NCT07393009","BIO|STREAM.CSP Study","Observation of Clinical Routine Care for Patients Implanted With BIOTRONIK Devices Used for Conduction System Pacing (CSP)","Inclusion Criteria:\n\n* Guideline indication for pacemaker or cardiac resynchronization therapy with or without defibrillation function (CRT-P\u002F-D)\n* Patient is intended for a de novo implantation and LBBAP therapy with an investigational generator and an investigational lead OR has just been implanted with an investigational generator and an investigational lead positioned permanently deep within the intraventricular septum and has not yet been discharged from the hospital OR transitions from the BIO\\|MASTER.CSP study\n* Ability to understand the nature of the study\n* Ability and willingness to perform all follow-up visits\n* Ability and willingness to use the CardioMessenger and acceptance of the BIOTRONIK Home Monitoring concept\n\nExclusion Criteria:\n\n* Planned dation from intended use\n* Planned for cardiac surgical procedures, heart transplantation or interventional measures other than the study procedure within one year after enrollment\n* Life-expectancy less than 12 months\n* Pregnant or breast feeding\n* Age less than 18 years\n* Participation in an interventional clinical investigation, except for submodules within this study.","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","4 Years","OBSERVATIONAL","The registry is designed to assess outcome, performance and residual safety aspects of BIOTRONIK products which are used in the context of CSP based on long-term data from an unselected, real-life clinical set-up.",[25,26,27,28,29,30,31],"Cardiac Pacing","Cardiac Pacemaker","Implantable Cardioverter Defibrillator","Cardiac Resynchronization Therapy Devices","Bradycardia","Tachycardia","Heart Failure",[33,34],"Conduction system pacing (CSP)","Left bundle branch area pacing (LBBAP)","RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-29","ACTUAL",{"date":41,"type":39},"2026-05-25",{"date":43,"type":20},"2033-02-01",{"name":45,"class":46},"Biotronik SE & Co. KG","INDUSTRY",40,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100642820","posterosuperior-bundle-pacing-for-prevention-of-atrial-fibrillation-in-patients-with-sinus-node-dysfunction-100642820","NCT07645066","Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction","A Prospective, Multicenter, Randomized Controlled Trial Evaluating the Effect of Posterosuperior Bundle Pacing on Atrial Fibrillation Prevention in Patients With Sinus Node Dysfunction","PSB-AF","Inclusion Criteria:\n\n* Age ≥18 years\n* Indication for permanent pacemaker implantation, including:\n* Sinus node dysfunction, defined as at least one of the following:\n* Symptomatic sinus bradycardia\n* Tachy-brady syndrome\n* Chronotropic incompetence\n* Sinus pause \u002F arrest\n* Atrioventricular block (if present); if ventricular pacing is required, left bundle branch area pacing is planned\n* Expected survival \\>1 year\n* Panned implantation of a device capable of detecting atrial high-rate episodes\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Persistent atrial fibrillation (AF) (\\>7 days), long-standing persistent AF, permanent AF, or prior atrioventricular node ablation\n* Prior cardiac implantable electronic device (CIED) requiring replacement, upgrade, or revision\n* Indication for cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT-D)\n* Prior cardiac surgery, severe hepatic or renal dysfunction, or other life-threatening systemic diseases\n* Acute myocardial infarction within 3 months before enrollment\n* Persistent left superior vena cava or dextrocardia\n* Pregnant or breastfeeding women, or women of childbearing potential not using effective contraception\n* Participation in another clinical trial that may interfere\n* Any condition that, in the opinion of the investigator, makes participation unsuitable",{"count":57,"type":20},300,"INTERVENTIONAL",[60],"NA","This study aims to evaluate whether posterosuperior bundle (PSB) pacing reduces the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND) undergoing pacemaker implantation. Approximately 300 patients will be enrolled and randomized to receive atrial pacing at either the PSB region or the right atrial appendage (RAA). The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes, as detected by device or surface electrocardiogram. Patients will be followed for up to 24 months.",[63,25],"Pacing Therapy",[65,66,67,68],"Posterosuperior bundle pacing","Right atrial appendage pacing","Physiological pacing","atrial pacing","NOT_YET_RECRUITING","2026-06-08",{"date":72,"type":39},"2026-06-12",{"date":74,"type":20},"2026-06-01",{"date":76,"type":20},"2029-02-01",{"name":78,"class":79},"Shanghai Tong Ren Hospital","OTHER",10,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":58,"phases":91,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100638160","av-nodal-ablation-with-conduction-system-pacing-versus-cardiac-resynchronization-for-symptomatic-heart-failure-patients-with-atrial-fibrillation-100638160","NCT07604727","AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation","AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation: The APAF-CSP All-cause Mortality and Quality of Life Trial","APAF-CSP","Inclusion Criteria:\n\n* Age 18 years or above.\n* Patient is diagnosed with AF and deemed not amenable to rhythm control. This diagnosis of AF will be demonstrated by at least one Electrocardiograph (ECG) showing AF that was performed within one year prior to enrollment.\n* Has history of stable heart failure (regardless left ventricular ejection fraction) and has a history of at least one HF related hospitalization or emergency room\u002Furgent care visit within 2 years prior to enrollment, despite being on maximally tolerable guideline directed medical therapy.\n* Willing and capable to provide informed consent.\n\nExclusion Criteria:\n\n* NYHA functional class IV.\n* Severe concomitant non-cardiac disease.\n* Patient who require any cardiac surgical intervention.\n* Previously implanted pacing devices (pacemaker\u002FICD\u002FCRT) with ≥40% pacing burden.\n* Any of the following within the 3 months prior to enrollment:\n\n  * Myocardial infarction\n  * Unstable angina\n  * Percutaneous coronary intervention\n  * Stroke or TIA\n  * Significant bleeding\n  * Pericarditis\u002Feffusions\n* Coronary artery bypass surgery\u002Fatriotomy within 6 months prior to enrolment.\n* Women who are pregnant or breastfeeding.",{"count":90,"type":20},292,[60],"The goal of this clinical trial is to learn if conduction system pacing works as well as cardiac resynchronization therapy (CRT) post atrioventricular (AV) node ablation in adult patients with symptomatic heart failure and atrial fibrillation that is not suitable for rhythm control.\n\nThe main question it aims to answer is:\n\nIs AV node ablation with conduction system pacing noninferior to AV node ablation with CRT for the hierarchical composite outcome of all-cause mortality, heart failure hospitalization or urgent heart failure visit, and meaningful improvement in heart failure-related quality of life?\n\nParticipants will undergo:\n\n* An AV node ablation and be randomly assigned to receive either a conduction system pacing or a CRT.\n* Attend follow-up visits (in clinic or by telephone) at baseline, intervention day, 3-month, 12-month, 24-month, and 36-month after the procedure.\n* Complete questionnaires about heart failure symptoms and quality of life at baseline, 12 months, and yearly.\n* Have an echocardiogram, an electrocardiogram, and blood tests at baseline and 1 year\n* At selected centers: they will be asked to wear a bracelet that measures arterial stiffness for 30 minutes and provide a urine sample at baseline and 1 year.",[94,31,25],"Atrial Fibrillation (AF)",[96,97,98,99,31,100,101,102,103,104,105,87,106,107,108],"Conduction System Pacing","Cardiac Resynchronization","Atrial Fibrillation","AV Nodal Ablation","All-cause Mortality","Quality of Life","HF hospitalization","Unplanned\u002Furgent HF visit","Arterial Stiffness Index","Photoplethysmography","EQ-5D","AFEQT","Kansas City Cardiomyopathy Questionnaire (KCCQ)","2026-05-19",{"date":111,"type":39},"2026-05-22",{"date":113,"type":20},"2026-07",{"date":115,"type":20},"2030-06",{"name":117,"class":79},"University Medical Center Groningen",23,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":58,"phases":129,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100638995","immediate-electrophysiological-effects-of-different-atrial-pacing-sites-on-p-wave-characteristics-100638995","NCT07603648","Immediate Electrophysiological Effects of Different Atrial Pacing Sites on P-Wave Characteristics","Prospective Within-Subject Evaluation of Immediate Electrophysiological Effects of Multiple Atrial Pacing Sites on Atrial Activation and P-Wave Morphology","Multi-site AP","Inclusion Criteria:\n\n* Age ≥18 years\n* Sinus rhythm at baseline\n* Indication for permanent pacemaker implantation with planned atrial lead placement\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Long-standing persistent or permanent atrial fibrillation, or prior atrioventricular node ablation\n* Prior cardiac implantable electronic device (CIED) requiring revision, replacement, or upgrade\n* Indication for implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D)\n* Significant valvular heart disease, cardiomyopathy, or prior cardiac surgery\n* Angina or acute myocardial infarction within 3 months before enrollment\n* Chronic use of antiarrhythmic drugs\n* Severe hepatic or renal dysfunction, or other serious systemic diseases\n* Participation in another clinical study that may interfere with the objectives of this study",{"count":128,"type":20},35,[60],"This is a prospective, single-center, non-randomized, within-subject interventional study. The purpose is to compare the immediate effects of different atrial pacing sites on atrial electrical activation, as reflected by P-wave characteristics on surface electrocardiography (ECG).\n\nDuring pacemaker implantation, short-term pacing will be performed sequentially at multiple predefined atrial sites, including the right atrial appendage (RAA), atrial septum, Bachmann's bundle (BB) area, and posterosuperior bundle (PSB) regions. ECG parameters will be recorded at each site to evaluate differences in P-wave duration and morphology.",[63,25],[68,133,134,65],"physiological pacing","Bachmann's bundle pacing","2026-05-18",{"date":111,"type":39},{"date":138,"type":39},"2026-03-31",{"date":140,"type":20},"2026-10-31",{"name":78,"class":79},2,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":58,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":168,"locationsCount":170},"100606301","cardiac-anodal-biphasic-pacing-100606301","NCT07173777","Cardiac Anodal Biphasic Pacing","ABP","Inclusion Criteria:\n\nCohort A\n\n• Planned interventional cardiac procedure\n\nCohort B\n\n* Planned generator exchange of dual chamber cardiac implantable electronic device (CIED)\n* Functioning atrial lead\n\nCohort C\n\n* Planned de novo implant or generator exchange of CIED with cardiac resynchronization therapy\n* Functioning atrial lead\n\nExclusion Criteria:\n\n* Permanent atrial fibrillation\n* Third degree AV block without stable escape rhythm\n* Ischemic heart disease or coronary disease \\> 40%\n* Unable to receive heparin\n* Are not fluent in English\n* Unable to read in English\n* Not able to provide informed consent\n* Women who are pregnant",{"count":151,"type":20},108,[60],"The goal of this study is to test a new pacing method called anodal biphasic pacing (ABP) to determine if this pacing works as well-or better-than current pacing methods. This new method may improve how the heart works and reduce some of the problems caused by regular pacing.\n\nCurrent implantable pacemakers use a monophasic cathodal waveform to stimulate the heart. Monophasic cathodal pacing (MCP) waveforms slow conduction, impair contractility, cause inflammation, increase risk of atrial fibrillation, heart failure, and mortality. Anodal biphasic pacing (ABP) is an alternative waveform that can stimulate the heart. ABP preconditions the heart and then initiates cardiac contraction. ABP may address the limitations of MCP.",[25],[156,157,158,159,160,161],"Anodal biphasic pacing (ABP)","Monophasic cathodal pacing (MCP)","Ejection fraction","Cardiac implantable electronic device","Cardiac contractility modulation","Implantable cardiac defibrillator","2026-04-27",{"date":164,"type":39},"2026-04-28",{"date":113,"type":20},{"date":167,"type":20},"2027-07",{"name":169,"class":79},"Boston Medical Center",1]